Vaxcyte and Lonza Join Forces to Expand Global Commercial Production of Pneumococcal Conjugate Vaccines
As the world continues to grapple with the devastating effects of the ongoing COVID-19 pandemic, another silent threat looms in the background - pneumococcal disease. With the aim to combat this major health concern, Vaxcyte, a leading biotechnology company focused on developing innovative vaccines, has announced an expansion of its collaboration with Lonza, a global leader in manufacturing technologies. Together, they are dedicated to establishing global commercial manufacturing capacity for Vaxcyte’s broad-spectrum pneumococcal conjugate vaccines (PCVs), namely VAX-24 and VAX-31, targeting both adult and pediatric populations.
Pneumococcal disease, caused by the bacteria Streptococcus pneumoniae, is known to cause severe illnesses such as pneumonia, meningitis, and bacteremia. Despite the availability of vaccines, this disease still takes a heavy toll on global health, with over 1.6 million deaths reported annually, predominantly in children under the age of five and older adults. In response to this ongoing public health crisis, Vaxcyte has been at the forefront of developing next-generation pneumococcal vaccines to provide global protection against a wider array of serotypes.
Under their expanded collaboration, Vaxcyte and Lonza are leveraging their respective expertise to establish a robust global commercial manufacturing capacity for VAX-24 and VAX-31. This new agreement builds upon Vaxcyte’s initial commercial launch plan for VAX-24 in adults, utilizing existing Lonza facilities in Visp, Switzerland. The partnership aims to ensure a seamless transition from clinical development to large-scale commercial supply, enabling timely access to these life-saving vaccines for individuals of all ages worldwide.
By combining Vaxcyte’s innovative research and development capabilities with Lonza’s extensive expertise in large-scale manufacturing, this collaboration will pave the way for increased access to PCVs for both pediatric and adult populations. Through the generation of additional doses, Vaxcyte and Lonza strive to address the global unmet need for effective protection against pneumococcal diseases.
VAX-24, the lead PCV candidate in Vaxcyte’s pipeline, is designed to provide broader protection by targeting 24 serotypes of the bacteria, including those responsible for the majority of invasive pneumococcal diseases worldwide. This vaccine has shown promising results in clinical trials, demonstrating safety and immunogenicity in both adults and infants.
Furthermore, Vaxcyte’s VAX-31 is currently being developed as a next-generation vaccine targeting 31 serotypes, increasing the potential coverage against pneumococcal infections. This product is expected to further enhance the immune response and broaden protection against pneumococcal diseases.
The expansion of global commercial manufacturing capacity represents a pivotal milestone for Vaxcyte. By ramping up production and securing reliable supply channels, this collaboration will address the increasing demand for PCVs and ensure global access to pneumococcal vaccination. Additionally, it will strengthen Vaxcyte’s market position as a leader in the fight against pneumococcal diseases, forging a path towards improved global health outcomes.
As the COVID-19 pandemic has starkly highlighted, vaccines remain our most effective defense against infectious diseases. The collaboration between Vaxcyte and Lonza sets a remarkable precedent in the field of vaccine development and manufacturing. By pooling their knowledge and resources, these companies are poised to deliver safe and effective PCVs, significantly reducing the burden of pneumococcal diseases on a global scale.
In conclusion, the expanded collaboration between Vaxcyte and Lonza for global commercial manufacturing of broad-spectrum pneumococcal conjugate vaccines is an important step towards combating pneumococcal diseases worldwide. Through their combined efforts, these companies aim to make significant strides in protecting individuals of all ages, offering hope for a healthier future. Together, Vaxcyte and Lonza are paving the way for improved immunization strategies and a world where pneumococcal diseases no longer pose a significant threat.
Comments